Johnson & Johnson offered $8.9 billion to settle years-old lawsuits claiming that its talcum powder products caused cancer.
The New Jersey-based pharmaceutical giant described their proposal, which still needs a bankruptcy court’s approval, as an equitable and efficient resolution to all claims arising from cosmetic talc litigation.
If approved by the bankruptcy court and a majority of the claimants, the $8.9 billion deal would rank alongside those reached by cigarette corporations and opioid producers as one of the largest product liability settlements ever in the US
Thousands of claims have been filed against J&J because of talcum powder that may have contained traces of asbestos and was linked to ovarian cancer.
The company has never acknowledged wrongdoing, but as of May 2020, it no longer sells its talc-based baby powder in the US and Canada.
The $8.9 billion would be paid to the tens of thousands of claimants over 25 years through a J&J subsidiary, LTL Management LLC, which was set up to address the claims and has filed for bankruptcy protection.
A previous settlement involving LTL was rejected by an appellate court.


Honduras Court Drops Charges Against Ex-President Juan Orlando Hernandez
Prince Harry Faces Potential Multi-Million-Pound Legal Bill in Daily Mail Case
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal
Huawei Launches Mate XT2 Foldable Phone in China
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates
Google Revamps EU Search Results to Meet DMA Rules
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities
Maduro Seeks Dismissal of US Drug Trafficking Charges
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports
Zara Owner Inditex Sales Rise 9% in August
Treasury Buyback Fails to Cool Long-Term Yields
Nvidia-Groq AI Chip Deal Faces U.S. Antitrust Probe
Nvidia Plans 2GW Australia AI Data Center Expansion by 2027
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
Iraq Seeks 6 Million Bpd OPEC+ Oil Quota
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 



